CSL Behring

🇧🇪Belgium

Country: 🇧🇪Belgium

Ownership: -

Employees: -

Market Cap: -

Website: http://www.cslbehring.com/

Clinical Trials

Quality of Life Study of Helixate NexGen

Completed

Conditions: Hemophilia A

First Posted Date: 2010-01-21

Last Posted Date: 2015-03-20

Lead Sponsor: CSL Behring

Target Recruit Count: 78

Registration Number: NCT01053715

Locations: 🇦🇹
CSLB Study Site 25, St. Pölten, Austria
🇦🇹
CSLB Study Site 23, Linz, Austria
🇫🇷
CSLB Study Site 65, Amiens, France

and more 28 locations

Observational Study of Prophylaxis and Treatment of Acute Perioperative Bleeding With Beriplex® P/N (Probe Study)

Completed

Conditions: Coagulation Protein Disorders
Perioperative Care
Blood Loss, Surgical

Interventions: Biological: Beriplex® P/N
Biological: Fresh Frozen Plasma (FFP) and Beriplex® P/N
Other: Fresh Frozen Plasma

First Posted Date: 2010-01-21

Last Posted Date: 2017-10-03

Lead Sponsor: CSL Behring

Target Recruit Count: 445

Registration Number: NCT01053169

Locations: 🇬🇧
Royal Blackburn Hospital, Blackburn, United Kingdom
🇬🇧
Royal Free Hospital, London, United Kingdom
🇬🇧
Derriford Hospital, Plymouth, United Kingdom

and more 3 locations

Health Related Quality of Life of Youth and Young Adults With Hemophilia A

Completed

Conditions: Hemophilia A

First Posted Date: 2009-12-18

Last Posted Date: 2013-12-10

Lead Sponsor: CSL Behring

Target Recruit Count: 48

Registration Number: NCT01034904

Locations: 🇨🇦
Sick Kids Hospital, Toronto, Ontario, Canada
🇨🇦
CHU Sainte-Justine, Montreal, Quebec, Canada

An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency

Phase 3

Completed

Conditions: Factor XIII Deficiency

Interventions: Biological: FXIII Concentrate (Human) (FXIII)

First Posted Date: 2009-07-24

Last Posted Date: 2012-10-12

Lead Sponsor: CSL Behring

Target Recruit Count: 61

Registration Number: NCT00945906

Locations: 🇺🇸
Study Site, Houston, Texas, United States
🇺🇸
Study site, Milwaukee, Wisconsin, United States

Study of a pd VWF/FVIII Concentrate, Biostate®, in Subjects With Von Willebrand Disease

Phase 2

Completed

Conditions: Von Willebrand Disease

Interventions: Biological: Biostate®

First Posted Date: 2009-07-17

Last Posted Date: 2017-10-03

Lead Sponsor: CSL Behring

Target Recruit Count: 22

Registration Number: NCT00941616

Locations: 🇺🇦
Study Site, Lviv, Ukraine

Fibrinogen Concentrate (Human) - Efficacy and Safety Study

Phase 3

Withdrawn

Conditions: Afibrinogenemia
Hypofibrinogenemia
Fibrinogen Deficiency

Interventions: Biological: Fibrinogen Concentrate, Human (FCH)
Biological: Cryoprecipitate

First Posted Date: 2009-06-09

Last Posted Date: 2023-02-06

Lead Sponsor: CSL Behring

Registration Number: NCT00916656

A Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency

Phase 3

Completed

Conditions: Factor XIII Deficiency

Interventions: Biological: FXIII Concentrate (Human)

First Posted Date: 2009-04-22

Last Posted Date: 2012-07-16

Lead Sponsor: CSL Behring

Target Recruit Count: 41

Registration Number: NCT00885742

Locations: 🇺🇸
Study, Miami, Florida, United States
🇪🇸
Study Site, Santa Cruz de Tenerife, Spain

A Study of the Use of Factor XIII Concentrate in Patients With Inherited FXIII Deficiency

Phase 2

Completed

Conditions: Factor XIII Deficiency

Interventions: Biological: FXIII Concentrate (Human)

First Posted Date: 2009-04-17

Last Posted Date: 2012-01-16

Lead Sponsor: CSL Behring

Target Recruit Count: 15

Registration Number: NCT00883090

Locations: 🇪🇸
Study Site, Santa Cruz de Tenerife, Spain

Study of a pd vWF/FVIII, Biostate®, in Subjects With Haemophilia A

Phase 2

Completed

Conditions: Hemophilia A

Interventions: Biological: Biostate® [SP]
Biological: Biostate® [RP]

First Posted Date: 2009-04-10

Last Posted Date: 2011-02-11

Lead Sponsor: CSL Behring

Target Recruit Count: 81

Registration Number: NCT00879541

Locations: 🇷🇺
Study Site, Moscow, Russian Federation

Safety, Efficacy and Pharmacokinetics Study of ALD518 in Patients With Active Rheumatoid Arthritis

Phase 2

Completed

Conditions: Arthritis, Rheumatoid

Interventions: Biological: Infusion without ALD518'
Biological: ALD518

First Posted Date: 2009-03-23

Last Posted Date: 2020-07-09

Lead Sponsor: CSL Behring

Target Recruit Count: 127

Registration Number: NCT00867516

Locations: 🇨🇦
K-W Musculoskeletal Research, Inc., Kitchener, Ontario, Canada
🇮🇳
Sushrut Hospital, Research Centre & Post Graduate Institute of Orthopaedics, Ramadaspeth, Nagpur, India
🇵🇱
Nonpublic Centre of Medical Care Reumed, Lublin, Poland

and more 23 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy